Roth Capital Initiates Coverage On Inovio Pharmaceuticals with Buy Rating, Announces $13 Price Target

Roth Capital analyst Jonathan Aschoff initiates coverage on Inovio Pharmaceuticals (NASDAQ:INO) with a Buy rating and a $13 price target.

Benzinga · 12/19/2019 11:20

Roth Capital analyst Jonathan Aschoff initiates coverage on Inovio Pharmaceuticals (NASDAQ:INO) with a Buy rating and a $13 price target.